Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This Phase 1 first-in-human single ascending dose study will be a randomized, double-blind, placebo-controlled investigation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06741086.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
41 participants in 8 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal